Learn more about investing in BiomeSense

Our team will get back to you soon to follow up on your inquiry.
Opt-In Checkbox
Longitudinal microbiome sampling.
* Data source: Crunchbase
Funding to Date*
* Data source: Crunchbase
Kevin Honaker, CEO
We essentially can't trust any microbiome study that isn't longitudinal. Change is the only constant when it comes to microbiome data. And gut-drug interactions at this resolution are huge for any drug discovery platform.
More than a trillion microbes in our gut, and over 700-1000 species. There are more bacteria than human cells in our body.

BiomeSense is developing an integrated biosensor & cloud-based bioinformatics platform to massively scale the collection and analysis of gut microbiome data, producing up to 30x the data for <10% of the cost compared to conventional methods. The enabling technology is a proprietary microfluidic biosensor that’s installed in the patient home, passively and continuously sampling the gut microbiome without any input from the patient.

The company’s first market is clinical research, exponentially increasing the data available during clinical trials. After this market, the company plans to rapidly move to clinical use as a companion / traditional diagnostic, and long-term, the ultimate vision is to become a widespread consumer product to enable everyone to track and understand their microbiome for better health.